USP 797 / USP 800 Compliance and Compounding Pharmacy Insurance: A 2026 Guide

The short answer first

USP 797 governs sterile compounding. USP 800 governs hazardous-drug handling. Together they define the compliance perimeter that specialty pharmacy underwriters are now treating as a precondition for coverage rather than a bonus credit.

The 2023 revision to USP 797 tightened beyond-use dating, raised the bar on environmental monitoring frequency, and made competency documentation explicit rather than assumed. Specialty pharmacy carriers writing compounding accounts in 2026 require current USP 797 documentation as a condition at new business and at renewal; lapses in monitoring logs, expired competency records, or unclosed Form 483 observations trigger non-renewal, restrictive endorsements, or premium loadings that can rival the cost of the underlying compliance work.

USP 800 sits alongside USP 797 with a separate set of insurance implications: workers compensation class code assignment, products liability scope where cross-contamination between hazardous and non-hazardous compounds is conceivable, and pollution liability gaps in standard property forms that do not contemplate cytotoxic waste streams.

The cheapest way to control your insurance cost on a compounding account is to keep inspection-readiness documentation current and accessible. Underwriters do not credit the documentation work directly, but the absence of it surfaces as price.

What USP 797 actually requires

USP 797 applies to any compounded sterile preparation (CSP) — anything administered into the bloodstream, into the eye, into the central nervous system, or otherwise into a body cavity expected to be sterile. The chapter does not care whether the pharmacy is a 503A traditional compounder or a 503B outsourcing facility; it applies to the activity, not the entity.

The chapter defines three categories of CSPs distinguished by the rigor of compounding environment and the corresponding beyond-use dating:

• Category 1 CSPs. Compounded in a segregated compounding area meeting limited environmental controls. Short BUDs — typically measured in hours at room temperature, days refrigerated.
• Category 2 CSPs. Compounded in an ISO Class 5 primary engineering control inside an ISO Class 7 buffer area, with appropriate ante-room separation and full environmental monitoring. Longer BUDs based on sterility testing requirements and storage conditions.
• Category 3 CSPs. Introduced in the 2023 revision. Highest rigor — full sterility testing, endotoxin testing, and stability data — supporting BUDs that can extend further than Category 2 when the testing program supports it.

Beyond-use dating under the 2023 revision is more restrictive than the 2008 version that many state boards previously adopted. The headline shifts: tighter BUDs for several Category 1 and Category 2 preparation classes, explicit BUD tables tied to sterility and stability evidence, and Category 3 introduced as a higher-rigor option that allows extended dating only with the testing program to back it.

Environmental monitoring is no longer a once-a-quarter exercise. The 2023 chapter specifies viable air sampling, surface sampling, total particle counting, and certification of primary engineering controls and secondary engineering controls on defined frequencies — typically monthly viable sampling for buffer areas, with more frequent surface sampling at high-risk locations. Sampling locations must be diagrammed and consistently sampled visit-to-visit so trend data is meaningful.

Competency documentation is the area most pharmacies underestimate. Every compounding pharmacist and technician must have documented initial qualification (didactic, hands-on, and observed competency including media-fill testing) and periodic requalification on a defined schedule. Competency files must exist for every individual compounding under the chapter, dated, and reviewable on inspection.

The 2023 revision: what changed

The chapter that took effect on November 1, 2023 replaced the long-used 2008 version. The structural changes that matter most for an operator and an underwriter:

• Reorganized chapter structure. The 2023 chapter is reorganized into clearer sections covering personnel, facility, sterility assurance, and quality assurance. State boards that had adopted the 2008 chapter by reference had to update their references; some states moved quickly, others took longer, and the lag created a window where the same activity was governed by two different rule sets depending on jurisdiction.
• BUD shortening for several categories. Several preparation classes that had been operating on 2008-era BUDs found themselves shortened under the 2023 tables. Operators who built their workflow around the prior BUDs needed to either retest, reformulate, or shorten their dating in the master formulation records.
• Tighter environmental monitoring frequencies. The 2023 chapter is more prescriptive about how often to sample, where to sample, and how to document. Pharmacies that had been monitoring quarterly and getting clean data found themselves needing to move to monthly or weekly cadences depending on the area.
• Explicit competency documentation. The chapter requires written documentation of initial qualification and requalification, including media-fill testing, gloved fingertip sampling, and observed gowning competency. Records must be on file for the duration the individual is compounding plus a defined retention period.
• Category 3 introduced. A new category for higher-rigor preparations that allows extended BUDs only when supported by sterility testing, endotoxin testing, and stability data. Most pharmacies do not need Category 3 capability, but for those who do, the testing infrastructure is non-trivial.

The Texas State Board of Pharmacy, like most state boards, has aligned its rules with the 2023 chapter. Texas-licensed compounding pharmacies should be operating under the 2023 framework with the state-specific overlays applicable to that license class. State-board overlays are generally additive — the state can require more, but cannot allow less than the federal-level USP standard.

USP 800: the hazardous-drug overlay

USP 800 is a separate chapter governing the handling, compounding, and disposal of hazardous drugs as defined by the NIOSH hazardous-drug list. The list includes a wide range of antineoplastics, certain hormones, certain antivirals, and other drugs with reproductive or genotoxic risk.

A compounding pharmacy that handles any NIOSH-listed drug falls within the scope of USP 800, even for activities short of compounding (receipt, storage, transport). The facility requirements are real-property changes, not just procedural changes:

• Negative-pressure compounding areas for hazardous-drug compounding, separated from non-hazardous compounding areas with appropriate pressure differential and air exchange rates.
• Separate storage for hazardous drugs, with appropriate ventilation and signage. Co-storage with non-hazardous drugs is not permitted.
• Containment primary engineering controls (CSTDs, BSCs, or CACIs depending on activity) selected and certified for the hazardous drug activity being performed.
• PPE and training for every individual handling the drugs, with documented initial training and periodic requalification, including donning and doffing protocol observations.
• Waste-stream and decontamination procedures that meet the chapter's containment standards, with documented decontamination of work surfaces and equipment on a defined schedule.

The insurance implications are not always obvious. Three areas where USP 800 compliance status materially affects coverage:

• Workers compensation class code. Pharmacies handling hazardous drugs may classify into different WC codes than non-hazardous compounding pharmacies. The classification affects rate. More importantly, an injury claim alleging hazardous-drug exposure surfaces the chapter compliance record as evidence in the WC defense; pharmacies without a clean USP 800 file have a weaker defense posture.
• Products liability cross-contamination scope. A non-hazardous compound that becomes contaminated with residue from a hazardous-drug operation creates a products liability event with a long potential tail. Pharmacies running both hazardous and non-hazardous compounding in the same facility need underwriters to understand the segregation; the underwriting application is the moment to demonstrate it.
• Pollution liability gaps. Standard property and general liability forms typically contain pollution exclusions that can apply to cytotoxic waste releases, decontamination events, or environmental contamination from a hazardous-drug spill. A pharmacy handling NIOSH-listed drugs without a separate pollution liability layer or a pollution carve-back has a real coverage gap that surfaces only when something goes wrong.

How carriers underwrite USP 797/800 compliance

Specialty pharmacy underwriters writing compounding accounts in 2026 typically request, at new business and at renewal:

• Current SOPs aligned with the 2023 USP 797 chapter (and USP 800 where applicable), with version dates and review history.
• Most recent state board of pharmacy inspection report, with documented closure of any observations.
• Environmental monitoring logs for the past 12 months, with sampling frequencies, results, and trend analysis.
• Cleanroom certification records for primary and secondary engineering controls within the past 6 months.
• Training and competency files for every compounding pharmacist and tech, including media-fill testing results and gloved fingertip sampling.
• Adverse event log and any open recalls, regulatory correspondence, or pending litigation.

A pharmacy carrying Joint Commission Medication Compounding Certification can usually present that as a quality signal that earns underwriting credit. The certification process requires alignment with USP 797 and USP 800 plus additional Joint Commission standards, and the on-site survey produces an independent third-party validation that underwriters take seriously. Not every pharmacy needs the certification — it is non-trivial to obtain and maintain — but for higher-volume sterile compounding operations the underwriting credit and the operational discipline often justify the investment.

What triggers non-renewal or a restrictive endorsement at renewal:

• Form 483 observations not closed out. An open observation from a state board or FDA inspection signals an ongoing compliance issue. Underwriters will hold a renewal pending closure or impose an exclusion specific to the area of the observation.
• Lapsed competency documentation. Competency files that have aged past the requalification date for individuals still compounding are a frequent finding. The fix is usually mechanical (run the requalification) but the lapse itself reads as a quality-system maturity issue.
• Repeat environmental monitoring failures. Out-of-spec monitoring results without documented investigation, root-cause analysis, and corrective action read as a quality system that is sampling but not learning. Underwriters see the pattern even when the pharmacy does not.
• Missing USP 800 segregation at facilities handling hazardous drugs. Co-located workflows without proper containment are a structural risk that no procedural fix addresses.

The common mistake at renewal is treating the underwriting application as a forms exercise. The application is the underwriter's primary diagnostic tool. A vague answer or a missing attachment surfaces as a price increase or a coverage restriction; a thorough answer with attached documentation surfaces as a credit or, more often, as the absence of a debit. The pharmacies that price best are not the ones with the cleanest history — they are the ones that present their history cleanly.

Inspection-readiness checklist

• Current SOPs aligned with 2023 USP 797 BUD tiers and Category 1/2/3 definitions, with version dates and review history.
• Environmental monitoring logs current per the standard's frequency, with sampling locations diagrammed and trend data reviewable.
• Cleanroom certification within the past 6 months for every primary engineering control and secondary engineering control on the floor.
• Training and competency documentation for every compounding pharmacist and tech, including initial qualification, media-fill testing, and periodic requalification.
• USP 800 hazardous-drug compliance documentation if NIOSH-listed drugs are handled — facility segregation, ventilation records, PPE training, and waste-stream procedures.
• State board of pharmacy inspection report from the most recent visit, with all observations documented as closed and supporting evidence on file.
• Insurance policy declarations and endorsement schedule reviewed in the past 90 days, with any new exclusions identified and addressed.
• Druggist professional liability limit ≥ $1M per occurrence / aggregate ≥ $3M, with verification that the form is occurrence-form and not claims-made.
• Joint Commission Medication Compounding Certification status documented — either current certification or a documented decision (with rationale) not to pursue it.
• Inspection-readiness binder accessible on-site for surprise visits, organized by chapter section, with the responsible pharmacist's contact information on the cover page.

Related glossary entries: USP 797 Sterile Compounding Compliance · USP 800 Hazardous Drug Handling · Druggist Professional Liability · Joint Commission Medication Compounding